Rein Therapeutics (RNTX)
NASDAQ:RNTX
Want to see RNTX full AI Analyst Report?
Top Page
Rein Therapeutics
(NASDAQ:RNTX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.00
▲(58.73% Upside)
Action:ReiteratedDate:04/08/26
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and cash burn with declining equity), partially offset by constructive technical momentum (price above key moving averages and positive MACD). Valuation is constrained by negative earnings and no dividend support, while the recent private placement is a modest positive for liquidity but reinforces financing dependence.
Positive Factors
Low Leverage
Very low debt materially reduces financial risk and interest burden for a clinical-stage biotech. This structural cushion gives management flexibility to prioritize R&D and clinical programs over near-term cash interest obligations, improving survival odds during multi‑quarter trials.
Negative Factors
Pre‑revenue with Persistent Losses
No product revenue and sustained large net losses mean the company cannot self-fund operations. Over multiple quarters this forces reliance on external capital, creates execution risk if financings stall, and removes the stabilizing effect of operating cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt materially reduces financial risk and interest burden for a clinical-stage biotech. This structural cushion gives management flexibility to prioritize R&D and clinical programs over near-term cash interest obligations, improving survival odds during multi‑quarter trials.
Read all positive factors
Rein Therapeutics (RNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$46.54M
Dividend YieldN/A
Average Volume (3M)228.95K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS Growth43.36%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-1.09
Shares Outstanding28,039,032
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$10.00Price Target Upside693.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.63
Revenue Forecast (FY)N/A
Rein Therapeutics Business Overview & Revenue Model
Company Description
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate...
How the Company Makes Money
null...
Rein Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -21.93M | -28.05M | -15.23K | -27.48K | -26.48K |
| Net Income | -49.87M | -62.88M | -15.73K | -27.33K | -26.16K |
Balance Sheet | |||||
| Total Assets | 24.16M | 69.24M | 106.01M | 22.01M | 48.48M |
| Cash, Cash Equivalents and Short-Term Investments | 3.21M | 12.87M | 17.31M | 21.24M | 45.93M |
| Total Debt | 0.00 | 0.00 | 48.00K | 33.00K | 162.00K |
| Total Liabilities | 7.24M | 14.85M | 99.12M | 3.38M | 4.58M |
| Stockholders Equity | 16.92M | 54.39M | 6.89M | 18.62M | 43.90M |
Cash Flow | |||||
| Free Cash Flow | -19.36M | -22.29M | -19.81M | -24.86M | -23.91M |
| Operating Cash Flow | -19.36M | -22.29M | -19.81M | -24.86M | -23.75M |
| Investing Cash Flow | 0.00 | 0.00 | 16.20M | 26.46M | -35.92M |
| Financing Cash Flow | 9.76M | 17.82M | 15.79M | 0.00 | 55.66M |
Rein Therapeutics Technical Analysis
Positive
1.26
Price Trends
1.29
Positive
1.32
Positive
1.31
Positive
Market Momentum
0.12
Negative
69.06
Neutral
83.24
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNTX, the sentiment is Positive. The current price of 1.26 is below the 20-day moving average (MA) of 1.42, below the 50-day MA of 1.29, and below the 200-day MA of 1.31, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 69.06 is Neutral, neither overbought nor oversold. The STOCH value of 83.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNTX.
Rein Therapeutics Risk Analysis
Rein Therapeutics disclosed 88 risk factors in its most recent earnings report. Rein Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rein Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $54.03M | -0.79 | -62.53% | ― | ― | 33.32% | |
52 Neutral | $65.63M | -0.66 | -81.69% | ― | ― | 38.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $46.54M | -0.59 | -281.00% | ― | ― | 43.36% | |
44 Neutral | $11.36M | -0.98 | -335.47% | ― | 16.05% | 27.95% | |
44 Neutral | $116.13M | -3.01 | -718.54% | ― | 58.85% | 44.37% |
* Healthcare Sector Average
RNTX
Rein Therapeutics
1.66
-0.10
-5.68%
KZR
Kezar Life Sciences
7.33
3.00
69.28%
VVOS
Vivos Therapeutics
0.84
-1.84
-68.58%
OKUR
OnKure Therapeutics
4.80
2.26
88.98%
RANI
Rani Therapeutics Holdings
0.94
-0.16
-14.73%
Rein Therapeutics Corporate Events
Private Placements and Financing
Rein Therapeutics Completes Private Placement of Notes
Positive
Mar 2, 2026
Rein Therapeutics disclosed that it has completed a private placement of notes under purchase agreements, relying on exemptions from registration under the U.S. Securities Act of 1933. The transaction was structured under Section 4(a)(2) and Rule ...
Executive/Board Changes
Rein Therapeutics Announces Immediate Board Director Resignation
Neutral
Feb 19, 2026
On February 16, 2026, Rein Therapeutics, Inc. announced that Manuel C. Alves Aivado, M.D., Ph.D., resigned from its Board of Directors with immediate effect. The company stated that his departure did not arise from any disagreement over operations...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.